Fractional Laser vs. Ultrasound for Periorbital Wrinkles

Launched by NORTHWESTERN UNIVERSITY · Feb 7, 2012

Keywords

ClinConnect Summary

This clinical trial is exploring two different treatments for reducing wrinkles around the eyes, specifically intense focused ultrasound and carbon dioxide-fractionated laser. The goal is to see which method works better in smoothing out wrinkles, including those pesky crow's feet. The study is currently active, but it's not looking for new participants at this time.

To be eligible for this trial, participants need to be between 35 and 60 years old and have moderate wrinkles around their lower eyelids and eyes. They should have lighter skin types (Fitzpatrick skin types I-III) and be able to understand and agree to participate in the study. However, there are some important exclusions: for example, individuals who have had certain cosmetic treatments on their face in the last few months or have specific skin conditions cannot participate. If selected, participants can expect to receive one of the two treatments and be monitored for results, helping researchers understand which option is more effective.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 35-60 years old male and female subjects with moderate lower eyelid rhytids and crowsfeet
• • 2. Subjects with Fitzpatrick skin type I-III.
• • 3. Subjects who are willing, have the ability to understand and provide informed consent, and are able to communicate with the investigator.
• Exclusion Criteria:
• • 1. Subjects who have received injectable soft-tissue augmentation materials to the face, or facial ablative resurfacing, within the past 6 months.
• • 2. Subjects who were received injectable botulinum toxin to the face, or any nonablative laser treatment to the face, within the past 3 months.
• • 3. Subjects who have local infections, open facial wounds, or other significant local skin disease that would interfere with periorbital treatment with energy devices.
• • 4. Subjects who are allergic to lidocaine or prilocaine.
• • 5. Subjects who have a history of abnormal scarring in the treatment area.
• • 6. Subject who have ectropion or or other eyelid disfigurement.
• • 7. Subjects who have history of isotretinoin use in the preceding year
• • 8. Pregnant or lactating individuals